Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?

被引：0
|
作者：
Alan Pollack
Eric M Horwitz
机构：
[1] Chair of the Department of Radiation Oncology and Head of the Prostate Cancer Research Program at Fox Chase Cancer Center,
[2] Associate Professor and the Clinical Director of the Department of Radiation Oncology at Fox Chase Cancer Center in Philadelphia,undefined
来源：
Nature Clinical Practice Oncology | 2005年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：12 / 13
页数：1
相关论文
共 50 条
  • [31] Androgen Receptor Targeted Therapy plus Radiotherapy in Metastatic Castration Resistant Prostate Cancer
    Massaro, Maria
    Facondo, Giuseppe
    Vullo, Gianluca
    Aschelter, Anna Maria
    Rossi, Alessandro
    De Sanctis, Vitaliana
    Marchetti, Paolo
    Osti, Mattia Falchetto
    Valeriani, Maurizio
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [32] Improved survival of men with metastatic prostate cancer treated with androgen deprivation therapy plus radiotherapy to the prostate
    Yano, Akihiro
    Kagawa, Makoto
    Takeshita, Hideki
    Okada, Yohei
    Morozumi, Makoto
    Kawakami, Satoru
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 (12) : 863 - 865
  • [33] A definite Radiotherapy with a Short Androgen Deprivation Therapy of 18 Months may be sufficient in Patients with localized Prostate Cancer with high Risk-factor compared to the Standard of 28 to 36 Months
    Boehmer, Dirk
    Sedlmayer, Felix
    Wiegel, Thomas
    Wolf, Frank
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (08) : 764 - 766
  • [34] Significance of Testosterone Suppression in Localized Prostate Cancer Treated with Androgen Deprivation Therapy and Radiotherapy: Data from 2 Phase 3 Trials
    Nabid, A.
    Marie-Pierre, G.
    Vigneault, E.
    Souhami, L.
    Lemaire, C.
    Brassard, M. A.
    Bahoric, B.
    Archambault, R.
    Vincent, F.
    Bettahar, R.
    Wilke, D. R.
    Nguyen-Huynh, T. V.
    Martin, A. G.
    Bahary, J. P.
    Duclos, M.
    Vass, S. T., Jr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S131 - S132
  • [35] Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer
    Nishiyama, Tsutomu
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2012, 129 (3-5): : 179 - 190
  • [36] BASELINE SERUM TESTOSTERONE IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER
    Roach, Mack, III
    Bae, Kyounghwa
    Lawton, Colleen
    Donnelly, B. J.
    Grignon, David
    Hanks, Gerald E.
    Porter, Arthur
    Lepor, Herbert
    Venketesan, Varagur
    Sandler, Howard
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (05): : 1314 - 1322
  • [37] Phase 2 study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high risk localized prostate cancer (HRLCaP)
    McKenzie, M.
    Chi, K.
    Neville, A.
    Ellard, S.
    Baerg, B.
    Ruether, D.
    Winquist, E.
    Segal, R.
    Attwell, A.
    Lukka, H.
    RADIOTHERAPY AND ONCOLOGY, 2006, 80 : S10 - S11
  • [38] Three Dimensional Conformal Radiotherapy and Androgen Deprivation Therapy in Patients with Clinically Localized Prostate Cancer; Hacettepe University Experience
    Ozdemir, Yurday
    Akyol, Fadil
    Ozyigit, Gokhan
    Hurmuz, Pervin
    Onal, Cem
    Selek, Ugur
    Karabulut, Erdem
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2015, 25 (02): : 107 - 117
  • [39] Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer
    Yang, D. D.
    Krasnova, A.
    Nead, K. T.
    Choueiri, T. K.
    Hu, J. C.
    Hoffman, K. E.
    Yu, J. B.
    Spratt, D. E.
    Feng, F. Y.
    Trinh, Q. -D.
    Nguyen, P. L.
    ANNALS OF ONCOLOGY, 2018, 29 (02) : 386 - 391
  • [40] Cardiovascular Disease Risk and Androgen Deprivation Therapy in Patients with Localized Prostate Cancer
    Haque, Reina
    Xu, Xiaoqing
    Yood, Marianne Ulcickas
    Cassidy-Bushrow, Andrea E.
    Van den Eeden, Stephen K.
    Potosky, Arnold L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 323 - 324
12345